Tags

Type your tag names separated by a space and hit enter

CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy.
Genet Med. 2015 Nov; 17(11):912-8.GM

Abstract

PURPOSE

Enzyme replacement therapy (ERT) with recombinant human acid α-glucosidase (rhGAA) prolongs survival in infantile Pompe disease (IPD). However, the majority of cross-reactive immunologic material (CRIM)-negative (CN) patients have immune responses with significant clinical decline despite continued ERT. We aimed to characterize immune responses in CN patients with IPD receiving ERT monotherapy.

METHODS

A chart review identified 20 CN patients with IPD treated with ERT monotherapy for ≥6 months. Patients were stratified by anti-rhGAA antibody titers: high sustained antibody titers (HSAT; ≥51,200) at least twice; low titers (LT; <6,400) throughout treatment; or sustained intermediate titers (SIT; 6,400-25,600).

RESULTS

Despite early initiation of treatment, the majority (85%) of CN patients developed significant antibody titers, most with HSAT associated with invasive ventilation and death. Nearly all patients with HSAT had at least one nonsense GAA mutation, whereas the LT group exclusively carried splice-site or frameshift mutations. Only one patient in the HSAT group is currently alive after successful immune modulation in the entrenched setting.

CONCLUSION

Immunological responses are a significant risk in CN IPD; thus induction of immune tolerance in the naive setting should strongly be considered. Further exploration of factors influencing immune responses is required, particularly with the advent of newborn screening for Pompe disease.

Authors+Show Affiliations

Department of Pediatrics, Division of Medical Genetics, Duke University Medical Center, Durham, North Carolina, USA.Department of Pediatrics, Division of Medical Genetics, Duke University Medical Center, Durham, North Carolina, USA.Department of Pediatrics, Division of Medical Genetics, Duke University Medical Center, Durham, North Carolina, USA.Department of Pediatrics, Division of Medical Genetics, Duke University Medical Center, Durham, North Carolina, USA.Department of Pediatrics, Division of Medical Genetics, Duke University Medical Center, Durham, North Carolina, USA.Department of Pediatrics, Division of Medical Genetics, Duke University Medical Center, Durham, North Carolina, USA.Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA.Department of Human Genetics, Emory University, Atlanta, Georgia, USA.Western Sydney Genetics Program, Children's Hospital at Westmead, Sydney, Australia.Western Sydney Genetics Program, Children's Hospital at Westmead, Sydney, Australia.Department of Pediatrics, Nutrition and Metabolic Diseases, The Children's Memorial Health Institute, Warsaw, Poland.Center for Pediatric and Adolescent Medicine, University Medical Center, Mainz, Germany.No affiliation info availableDepartment of Pediatrics, Division of Medical Genetics, Duke University Medical Center, Durham, North Carolina, USA.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25741864

Citation

Berrier, Kathryn L., et al. "CRIM-negative Infantile Pompe Disease: Characterization of Immune Responses in Patients Treated With ERT Monotherapy." Genetics in Medicine : Official Journal of the American College of Medical Genetics, vol. 17, no. 11, 2015, pp. 912-8.
Berrier KL, Kazi ZB, Prater SN, et al. CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genet Med. 2015;17(11):912-8.
Berrier, K. L., Kazi, Z. B., Prater, S. N., Bali, D. S., Goldstein, J., Stefanescu, M. C., Rehder, C. W., Botha, E. G., Ellaway, C., Bhattacharya, K., Tylki-Szymanska, A., Karabul, N., Rosenberg, A. S., & Kishnani, P. S. (2015). CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genetics in Medicine : Official Journal of the American College of Medical Genetics, 17(11), 912-8. https://doi.org/10.1038/gim.2015.6
Berrier KL, et al. CRIM-negative Infantile Pompe Disease: Characterization of Immune Responses in Patients Treated With ERT Monotherapy. Genet Med. 2015;17(11):912-8. PubMed PMID: 25741864.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. AU - Berrier,Kathryn L, AU - Kazi,Zoheb B, AU - Prater,Sean N, AU - Bali,Deeksha S, AU - Goldstein,Jennifer, AU - Stefanescu,Mihaela C, AU - Rehder,Catherine W, AU - Botha,Eleanor G, AU - Ellaway,Carolyn, AU - Bhattacharya,Kaustuv, AU - Tylki-Szymanska,Anna, AU - Karabul,Nesrin, AU - Rosenberg,Amy S, AU - Kishnani,Priya S, Y1 - 2015/03/05/ PY - 2014/10/28/received PY - 2014/12/31/accepted PY - 2015/3/6/entrez PY - 2015/3/6/pubmed PY - 2016/9/10/medline SP - 912 EP - 8 JF - Genetics in medicine : official journal of the American College of Medical Genetics JO - Genet. Med. VL - 17 IS - 11 N2 - PURPOSE: Enzyme replacement therapy (ERT) with recombinant human acid α-glucosidase (rhGAA) prolongs survival in infantile Pompe disease (IPD). However, the majority of cross-reactive immunologic material (CRIM)-negative (CN) patients have immune responses with significant clinical decline despite continued ERT. We aimed to characterize immune responses in CN patients with IPD receiving ERT monotherapy. METHODS: A chart review identified 20 CN patients with IPD treated with ERT monotherapy for ≥6 months. Patients were stratified by anti-rhGAA antibody titers: high sustained antibody titers (HSAT; ≥51,200) at least twice; low titers (LT; <6,400) throughout treatment; or sustained intermediate titers (SIT; 6,400-25,600). RESULTS: Despite early initiation of treatment, the majority (85%) of CN patients developed significant antibody titers, most with HSAT associated with invasive ventilation and death. Nearly all patients with HSAT had at least one nonsense GAA mutation, whereas the LT group exclusively carried splice-site or frameshift mutations. Only one patient in the HSAT group is currently alive after successful immune modulation in the entrenched setting. CONCLUSION: Immunological responses are a significant risk in CN IPD; thus induction of immune tolerance in the naive setting should strongly be considered. Further exploration of factors influencing immune responses is required, particularly with the advent of newborn screening for Pompe disease. SN - 1530-0366 UR - https://www.unboundmedicine.com/medline/citation/25741864/CRIM_negative_infantile_Pompe_disease:_characterization_of_immune_responses_in_patients_treated_with_ERT_monotherapy_ L2 - http://dx.doi.org/10.1038/gim.2015.6 DB - PRIME DP - Unbound Medicine ER -